


6p 1654  
Bhu/B



98204.00019

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Robert H. Zimmer ) Examiner: Teller, Roy R.  
Serial No.: 10/050,903 ) Group Art Unit: 1654  
Filed: January 16, 2002 ) Confirmation No. 5841

For: PROCESS TO IMPROVE OR PERMIT THE ORAL ABSORPTION OF  
POLYPEPTIDE DRUG SUBSTANCES AND OTHER POORLY ORALLY  
ABSORBED DRUGS WHILE MAINTAINING THEIR  
PHARMACOLOGICAL EFFECTS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the documents listed on the attached form  
PTO-1449 are being brought to the attention of the Examiner for consideration in  
connection with examination of the above-identified patent application.

This Supplemental Information Disclosure Statement is being filed after the  
mailing date of a Notice of Allowance in connection with the present application. (See 37  
CFR § 1.98(d)).

Applicant hereby requests that the documents submitted herewith be placed of  
record in the file for the present application pursuant to 37 CFR § 1.98(i).\

The filing of this Supplemental Information Disclosure Statement shall not be construed to be a representation that a search has been conducted, nor shall it be construed as an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

Respectfully submitted,

Date: October 18, 2004




Basam E. Nabulsi  
Reg. No. 31,645  
Attorney for Applicants

McCarter & English, LLP  
Four Stamford Plaza  
107 Elm Street  
Stamford, CT 06902  
(203) 965-0601

I hereby certify that the enclosed Supplemental Information Disclosure Statement along with a PTO-1449 Form and cited references is being deposited with the United States Postal Service as first class mail, postage prepaid, addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on October 18, 2004.

Dated: October 18, 2004

  
Joan Simmons

HARTFORD: 625066.01

Form PTO-1449 (modified 2/91)	U.S. DEPT OF COMMERCE Patent and Trademark Office	Attorney Docket Number:  98204.00019	Serial No.:  10/050,903
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		Applicants:	
		Robert H. Zimmer	
		Filing date: 1/16/02	Group Art Unit: 1654



## U.S. PATENT DOCUMENTS

Examiner Initial	Patent number	Date	Inventor	Class	Sub class	Filing date if appropriate
	4,239,754	12/16/1980	Sache et al.			
	4,339,534	7/13/1982	Johansen et al.			
	4,396,606	8/2/1983	Goldstein			
	4,694,006	9/15/1987	Bundgaard et al.			
	4,925,673	5/15/1990	Steiner et al.			
	5,212,158	5/18/1993	Vandai			

## FOREIGN PATENT DOCUMENTS

	Document number	Date	Country	Class	Sub class	Translation Yes No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Ahlers, et al., Enhanced Immunogenicity of HIV-1 Vaccine Construct By Modification of the Native Peptide Sequence, Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 10856-10861, September 1997.
	Greenstein, et al., A Universal T Cell Epitope-Containing Peptide From Hepatitis B Surface Antigen Can Enhance Antibody Specific For HIV gp120, Journal of Immunology, Vol. 148, pp. 3970-3977, No. 12, June 1992.
	Belyakov, et al., The Importance of Local Mucosal HIV-Specific CD8 <sup>+</sup> Cytotoxic T Lymphocytes For Resistance to Mucosal Viral Transmission in Mice and Enhancement of Resistance by Local Administration of IL-12, The Journal of Clinical Investigation, Vol. 102(12); pp. 2072-2081, December 1998.
	Belyakov, et al., Mucosal Immunization With HIV-1 Peptide Vaccine Induces Mucosal and Systemic Cytotoxic T Lymphocytes and Protective Immunity In Mice Against Intrarectal Recombinant HIV_Vaccinia Challenge, Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 1709-1714, February 1998.
	Patel, et al., Oral Administration of Insulin By Encapsulation Within Liposomes, North-Holland Publishing Company, Volume 62, No. 1, pp. 60-63, February 1976.
	Hashimoto, et al., ACTH Release in Pituitary Cell Cultures, Effect of Neurogenic Peptides and Neurotransmitter Substances Corticotropin Releasing Factor (CRF), Endocrinol. Japan, Vol. 26 (1), pp. 103-109, February 1979.

Examiner:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	